Jesse Fishman

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 10

Top Topics

Obstructive Sleep Apnea

Ejection Fraction

Patient Reported

Top Venues

Hematology reports

Journal of clinical medicine

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Carolyn Emily Schwartz, Katrina Borowiec, Jinny Min, Jesse Fishman
Fatigue Item Response among Hemoglobin-Normalized Patients with Paroxysmal Nocturnal Hemoglobinuria: PEGASUS Trial Results at 16 and 48 Weeks. Journal of clinical medicine 13 (6) (2024)
Carolyn Emily Schwartz, Katrina Borowiec, Jinny Min, Jesse Fishman
Fatigue Item Response among Hemoglobin-Normalized Patients with Paroxysmal Nocturnal Hemoglobinuria: PEGASUS Trial Results at 16 and 48 Weeks. Journal of clinical medicine 13 (6) (2024)
Jesse Fishman, Yestle Kim, Helene Parise, Eric M Bercaw, Zachary Smith
Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Journal of medical economics 27 (1) (2024)
Jesse Fishman, Yestle Kim, Helene Parise, Eric M Bercaw, Zachary Smith
Budget impact of resmetirom for the treatment of adults with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Journal of medical economics (2024)
Jesse Fishman, Seth Kuranz, Michael M Yeh, Kaylen Brzozowski, Herman Chen
Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. Hematology reports 15 (2) (2023)
Jesse Fishman, Seth Kuranz, Michael M Yeh, Kaylen Brzozowski, Herman Chen
Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. Hematology reports 15 (2) (2023)
Jesse Fishman, Seth Kuranz, Michael M Yeh, Kaylen Brzozowski, Herman Chen
Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. Hematology reports 15 (2) (2023)
Jesse Fishman, Seri Anderson, Sandra E Talbird, David Dingli
Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment. Hematology reports 15 (4) (2023)
Jesse Fishman, Seth Kuranz, Michael M Yeh, Kaylen Brzozowski, Herman Chen
Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. Hematology reports 15 (2) (2023)
Jesse Fishman, Seth Kuranz, Michael M Yeh, Kaylen Brzozowski, Herman Chen
Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. Hematology reports 15 (2) (2023)